TWI PHARMS
Big PharmaTWI PHARMS is a major pharmaceutical company focused on Cardiovascular, Immunology, Neurology. Key products include FORFIVO XL.
TWI PHARMS's Key Drugs
TWI PHARMS's core commercial portfolio centers on FORFIVO XL, spanning Cardiovascular and Immunology — its most strategically important drugs approved in the last 15 years.
TWI PHARMS's Recent FDA Approvals
New NDA/BLA approvals for TWI PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
TWI PHARMS's Therapeutic Areas
TWI PHARMS's approved drugs and pipeline span 4 therapeutic areas, led by Cardiovascular and Immunology, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
TWI PHARMS's Top Competitors
TWI PHARMS's closest competitors by therapeutic-area and drug-target overlap include Novartis, LEDERLE, and UPJOHN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
TWI PHARMS Pipeline Snapshot
Active clinical trials for TWI PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • FORFIVO XL leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (1)
Company Info
- First Approval
- 1981-08-19
- Latest
- 2026-01-21
- Applications
- 32